tradingkey.logo

Champions Oncology Inc

CSBR
查看詳細走勢圖
7.220USD
0.000
收盤 12/19, 16:00美東報價延遲15分鐘
99.55M總市值
33.44本益比TTM

Champions Oncology Inc

7.220
0.000
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

+7.44%

1月

+6.65%

6月

-12.91%

今年開始到現在

-15.75%

1年

-3.80%

查看詳細走勢圖

TradingKey Champions Oncology Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Champions Oncology Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名50/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價12.00。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Champions Oncology Inc評分

相關信息

行業排名
50 / 404
全市場排名
146 / 4582
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 1 分析師
買入
評級
12.000
目標均價
+91.69%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Champions Oncology Inc亮點

亮點風險
Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
業績增長期
公司處於發展階段,最新年度總收入56.94M美元
業績轉盈
公司業績轉盈,最新年度盈利美元
估值高估
公司最新PE估值33.44,處於3年歷史高位
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉333.26K股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.11

Champions Oncology Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Champions Oncology Inc簡介

Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
公司代碼CSBR
公司Champions Oncology Inc
CEOBrainin (Robert)
網址https://championsoncology.com

常見問題

Champions Oncology Inc(CSBR)的當前股價是多少?

Champions Oncology Inc(CSBR)的當前股價是 7.220。

Champions Oncology Inc 的股票代碼是什麼?

Champions Oncology Inc的股票代碼是CSBR。

Champions Oncology Inc股票的52週最高點是多少?

Champions Oncology Inc股票的52週最高點是11.990。

Champions Oncology Inc股票的52週最低點是多少?

Champions Oncology Inc股票的52週最低點是5.592。

Champions Oncology Inc的市值是多少?

Champions Oncology Inc的市值是99.55M。

Champions Oncology Inc的淨利潤是多少?

Champions Oncology Inc的淨利潤為4.70M。

現在Champions Oncology Inc(CSBR)的股票是買入、持有還是賣出?

根據分析師評級,Champions Oncology Inc(CSBR)的總體評級為買入,目標價格為12.000。

Champions Oncology Inc(CSBR)股票的每股收益(EPS TTM)是多少

Champions Oncology Inc(CSBR)股票的每股收益(EPS TTM)是0.216。
KeyAI